FIELD: biotechnology.
SUBSTANCE: present invention relates to biotechnology, specifically to framework structures based on FnIII-domain tenascin-3 (Tn3). Invention enables to obtain a framework structure capable of specifically binding CD40L and having high affinity for the target compared to known analogues.
EFFECT: constructed frame structures of the present invention can be used as preventive, diagnostic or therapeutic agents, particularly for therapeutic applications against SLE and other autoimmune diseases and conditions.
41 cl, 19 dwg, 10 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TRAIL R2-SPECIFIC MULTIMERIC SCAFFOLDS | 2011 |
|
RU2628699C2 |
| COMPOSITIONS BASED ON STABILIZED FIBRONECTIN DOMAINS, METHODS AND AREAS OF APPLICATION THEREOF | 2011 |
|
RU2603272C2 |
| IL-12 COMPOSITIONS AIMED AT EDB | 2019 |
|
RU2758143C1 |
| BISPECIFIC ANTIBODIES SPECIFIC TO PD1 AND TIM3 | 2016 |
|
RU2729371C1 |
| NEW BISPECIFIC ANTIGEN-BINDING MOLECULES WITH CAPABILITY OF SPECIFICALLY BINDING TO CD40 AND FAP | 2018 |
|
RU2766234C2 |
| ANTIBODIES AGAINST HUMAN CD19 WITH HIGH AFFINITY | 2016 |
|
RU2761077C1 |
| INHIBITORS OF RECEPTORS OF TYPE 2 VESSEL ENDOTHELIUM GROWTH FACTOR | 2004 |
|
RU2402567C2 |
| RECOMBINANT PROTEINS AND THEIR APPLICATIONS IN THERAPEUTIC PURPOSES | 2018 |
|
RU2766595C2 |
| NOVEL SPECIFIC BINDING POLYPEPTIDES AND ROUTES OF USE THEREOF | 2015 |
|
RU2723034C2 |
| ANTAGONISTS AND METHOD OF USING SAID ANTAGONISTS | 2005 |
|
RU2401842C2 |
